During the pandemic, Moderna's (NASDAQ: MRNA) billion-dollar revenue has been pretty much a sure thing. The coronavirus vaccine maker shares leadership with Pfizer. And the two companies' vaccines have found their spot among the world's best-selling pharmaceutical products. As a result, Moderna's shares have climbed more than 140% since the launch of its vaccine program.

But in recent times, investors have turned away from Moderna shares. That's because of uncertainty about post-pandemic vaccine sales. Today, though, Moderna has offered us a few clues that should remove at least some of that uncertainty. Let's check out three things you need to know about Moderna's post-pandemic revenue -- and find out if these points make the biotech a stock to buy.

About 78% of the U.S. adult population has opted for a coronavirus vaccine so far. That's a high percentage. But this is in the context of a pandemic. The concern is that people's interest in getting vaccinated could drop off considerably once the pandemic is over.

Continue reading

Source Fool.com